In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mind Medicine, Inc.

https://www.mindmed.co/

Latest From Mind Medicine, Inc.

Merck Plans To ‘Tuck In’ Imago And Its Phase III-Ready Hematologic Candidate

After not closing a deal this year on Seagen, Merck takes a smaller step with a $1.35bn bid for Imago and its candidate for multiple myeloproliferative neoplasm indications.

M & A Business Strategies

Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates

While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.

Neurology Innovation

Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates

While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.

Neurology Innovation

More De-Risking Required Before Pharma Dives Into Psychedelics

One of the best-attended sessions at the BIO meeting in San Diego saw psychedelics specialists weighing up the sector's chances of breaking taboos and getting to market.

Neurology Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Digital Health
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • HealthMode
    • MindMed
UsernamePublicRestriction

Register